Drug Trial Radar · NCT04499248
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Nov 16, 2020
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Conditions
- Open-angle Glaucoma
- Ocular Hypertension
Interventions
AGN-193408 SRDrug
An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
LumiganOther
Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
Sham AdministrationOther
Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
Lumigan VehicleOther
Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
AGN-193408 SRDrug
An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
Sham AdministrationOther
Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
Lumigan VehicleOther
Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study EyeTime frame: Baseline to Month 36
- Number of participants experiencing treatment emergent adverse eventsTime frame: Baseline to Month 36
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153
Sun City, Arizona
Global Research Management /ID# 241699
Glendale, California
United Medical Research Institute /ID# 241701
Inglewood, California
Lakeside Vision Center /ID# 241698
Irvine, California
The Eye Research Foundation /ID# 234528
Newport Beach, California
Sacramento Eye Consultants /ID# 241697
Sacramento, California
Premiere Practice Management LLC /ID# 235957
Torrance, California
Wolstan & Goldberg Eye Associates /ID# 241700
Torrance, California
Connecticut Eye Consultants P.C. /ID# 235862
Danbury, Connecticut
Brandon Eye Associates - Brandon /ID# 276600
Brandon, Florida
Nature Coast Clinical Research - Crystal River /ID# 237781
Crystal River, Florida
Advanced Research, LLC /ID# 276987
Deerfield Beach, Florida
University of Florida Health Ophthalmology - Jacksonville /ID# 243122
Jacksonville, Florida
East Florida Eye Institute /ID# 235762
Stuart, Florida
Logan Ophthalmic Research Inc. /ID# 252087
Tamarac, Florida
Coastal Research Associates /ID# 234649
Roswell, Georgia
Thomas Eye Group PC /ID# 266775
Sandy Springs, Georgia
University of Illinois Hospital and Health Sciences System /ID# 253630
Chicago, Illinois
Midwest Medical Advisors Inc /ID# 235845
Carmel, Indiana
Indiana University - Glick Eye Institute /ID# 235887
Indianapolis, Indiana
Ophthalmic Consultants of Boston /ID# 236535
Boston, Massachusetts
Fraser Eye Care Center /ID# 267100
Fraser, Michigan
Midwest Vision Research Foundation at Pepose Vision Institute /ID# 267094
Chesterfield, Missouri
Silverstein Eye Centers /ID# 266767
Kansas City, Missouri
Tekwani Vision Center /ID# 235149
St Louis, Missouri
Nv Eye Surgery - Henderson /ID# 276925
Henderson, Nevada
Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 234365
Newark, New Jersey
Northern New Jersey Eye Institute /ID# 241545
South Orange, New Jersey
Asheville Eye Associates /ID# 234963
Asheville, North Carolina
Private Practice - Dr. James D. Branch /ID# 234560
Winston-Salem, North Carolina
The Ohio State University /ID# 267590
Columbus, Ohio
Oklahoma Eye Surgeons /ID# 252089
Oklahoma City, Oklahoma
Drs Fine Hoffman & Sims LLC /ID# 235919
Eugene, Oregon
Scott and Christie and Associates /ID# 252284
Cranberry Township, Pennsylvania
Eye Specialty Group /ID# 252201
Memphis, Tennessee
Vanderbilt Eye Institute /ID# 266915
Nashville, Tennessee
Advancing Vision Research /ID# 236683
Smyrna, Tennessee
Macro Trials (SMO/Network/Consortium) /ID# 266772
Austin, Texas
San Antonio Eye Center /ID# 272087
San Antonio, Texas
St. George Eye Center /ID# 236200
St. George, Utah
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.